Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Clinical and Vaccine Immunology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
VACCINE RESEARCH

Characterization and Use of Mammalian-Expressed Vaccinia Virus Extracellular Membrane Proteins for Quantification of the Humoral Immune Response to Smallpox Vaccines

Alonzo D. García, Clement A. Meseda, Anne E. Mayer, Arunima Kumar, Michael Merchlinsky, Jerry P. Weir
Alonzo D. García
Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alonzo.garcia@fda.hhs.gov
Clement A. Meseda
Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne E. Mayer
Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arunima Kumar
Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Merchlinsky
Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerry P. Weir
Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/CVI.00050-07
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Diagram of SFV genome and replicon constructs. (A) A diagram of the plus-stranded native RNA genome of SFV. (B) Representations of rSFV replicon vector constructs that encode prC epitope-tagged EV A33R, A34R, A56R, B5R, and GFP genes. The nonstructural genes encoding the replicase complex are indicated by nsP1, nsP2, nsP3, and nsP4. Helper vectors designated Helper C and Helper S encode the genes for the capsid (C) and the spike proteins (E1, E2, E3, and 6K), respectively. Large black arrow (SP6 pol) denotes the SP6 RNA polymerase promoter region; small black arrow denotes the 26S subgenomic promoter; black circle at 5′-end denotes CAP structure. An, polyA; PS, packaging signal; ΔnsP1-4, deleted nonstructural genes.

  • FIG. 2.
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Anti-Dryvax immune mouse serum recognizes rEV proteins. (A) Affinity-purified recombinant A33R, A34R, A56R, and B5R were analyzed under reducing conditions by using SDS-PAGE and SYPRO Ruby protein gel staining. Stained gel with lanes corresponding to (M) marker proteins and the indicated EV proteins is shown. Recombinant A33R, A34R, A56R, and B5R were treated with (+) and without (−) β-mercaptoethanol (β-ME) and were analyzed by SDS-PAGE and Western blotting using an anti-prC MAb (1/1,000 dilution) to the C-terminal prC epitope tag (B) or using a mouse anti-Dryvax antiserum (anti-Dryvax; 1/500 dilution) (C). Protein bands were detected by chemiluminescence after membranes were incubated with an anti-mouse IgG antibody conjugated to HRP (1/2,500 dilution). The positions and masses of the marker proteins are indicated on the left. Dots show the positions of EV protein bands that are consistent with the reported molecular mass for each of the indicated proteins (52).

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Analysis of immune serum from mice immunized with an HA deletion mutant vaccinia virus strain and noninfectious MV particles. (A) Hyperimmune antiserum anti-vA5Lint was obtained from BALB/c mice inoculated i.p. with a recombinant WR-strain vaccinia virus that lacks the A56R (HA) gene, vA5Lint, using a prime-boost schedule. (B) Hyperimmune antiserum anti-MV was obtained from mice inoculated s.c. with noninfectious WR strain vaccinia virus MV particles (4.0 × 107 PFU equivalents) using a prime-boost schedule. A33R, A34R, A56R, and B5R protein preparations were treated with (+) and without (−) β-mercaptoethanol (β-ME) prior to SDS-PAGE and protein transfer onto PVDF membranes. The PVDF membranes were incubated with mouse immune sera, followed by a second incubation with an anti-mouse IgG antibody conjugated to HRP. Protein bands were detected by chemiluminescence. Masses of protein markers are indicated on the left.

  • FIG. 4.
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    EV-specific antibody response induced by vaccinia virus. (A) A set of pooled anti-vaccinia virus antisera referred to as anti-vaccinia, anti-vA5Lint, and anti-MV was produced in BALB/c mice (in groups of three) that were inoculated with the MVA-Dryvax combination (107 PFU), live vA5Lint (107 PFU), and noninfectious WR strain MV particles (4.0 × 107 PFU equivalents), respectively, using a prime-boost schedule. Antisera were collected 3 weeks after the last inoculation, and pooled antisera were analyzed by ELISA using plates coated with EV proteins A33R, A56R, or B5R or UV-inactivated Dryvax MV particles. As a control, ELISA plates were probed with normal (uninoculated) mouse serum (NMS). (B) A group of mice were immunized i.d. with a single dose of 106 PFU of Dryvax, and antisera were collected at weeks 3, 6, and 9 postvaccination and pooled. Levels of antibodies to indicated EV proteins were measured by ELISA. The results shown in panels A and B were derived from a single experiment. α, anti.

  • FIG. 5.
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    EV-specific antibody titers in VIG. The EV-specific antibody titer in human VIG-IV was determined by ELISA for each indicated EV protein. Control human serum (NHS) is indicated.

  • FIG. 6.
    • Open in new tab
    • Download powerpoint
    FIG. 6.

    EV neutralization activity detected in anti-vaccinia virus hyperimmune sera. (A) Comet inhibition assays were performed using Vero cell monolayers infected with vaccinia virus (IHD-J) that were overlaid with medium alone, medium containing methyl cellulose (MC), or medium containing a 1/50 dilution of hyperimmune sera generated against Dryvax in mice (anti-Dryvax) or humans (Dryvax-VIG); (B) infected Vero cell monolayers were overlaid with medium containing a 1/50 dilution of mouse hyperimmune antisera anti-MV, anti-A5Lint, and anti-Dryvax (described in Fig. 3 legend). α, anti.

  • FIG. 7.
    • Open in new tab
    • Download powerpoint
    FIG. 7.

    Antibody response to rSFV infectious vectors expressing EV proteins. Mice in groups of five were inoculated s.c., using a prime-boost regimen, with 106 I.U. of indicated rSFV particles expressing GFP, A33R, A34R, A56R, or B5R or with 106 PFU of Dryvax. The inoculations were administered 3 weeks apart, and immune sera were collected 3 weeks after each injection and analyzed by single-EV-antigen ELISAs. (A) Antibody levels in antisera measured after the first inoculations. (B) Antibody levels measured after the second inoculations. Note: two out of five (2/5) mice inoculated once with rSFV-B5R seroconverted, whereas that none of the five (0/5) mice inoculated once with Dryvax had detectable antibody against B5R. After the second inoculation, all mice seroconverted.

  • FIG. 8.
    • Open in new tab
    • Download powerpoint
    FIG. 8.

    Western blot analysis of vaccinia virus-infected cells using rSFV vector-generated EV-specific antisera. Immune sera were collected from mice inoculated with two s.c. doses of 106 I.U. of rSFV particles encoding either A33R, A56R, or B5R and analyzed by Western blotting using uninfected and vaccinia virus-infected B-SC-1 cell lysates. B-SC-1 cells were infected at a multiplicity of infection of 5 with WR strain vaccinia virus (WR), Dryvax, and recombinant WR strain vaccinia virus vA5Lint (described in Fig. 3 legend). Indicated cell lysates were analyzed by Western blotting using antisera anti-A33R (A), anti-A56R (B), or anti-B5R (C) and an anti-mouse Ig-HRP conjugate. Indicated affinity-purified EV proteins A33R, A56R, and B5R were used as positive controls, and uninfected-cell lysate (uninf.) was used as a negative control. Molecular masses are indicated on the left. α, anti.

Tables

  • Figures
  • TABLE 1.

    Comparison of EV-specific antibody titers elicited by a single immunization with Dryvax or MVAa

    GroupType of immunizationRouteaDoseAntibody titer (log10 ± SD) against EV antigen:
    A33RA56RB5R
    1PBSi.m.NA0.10 ± 0.000.10 ± 0.000.10 ± 0.00
    2Dryvaxi.d.1063.40 ± 0.423.25 ± 0.212.50 ± 1.27
    3MVAi.m.1072.95 ± 0.213.11 ± 0.002.95 ± 0.21
    4MVAs.c.1072.05 ± 0.212.95 ± 0.213.11 ± 0.42
    5MVAi.d.1073.25 ± 0.643.11 ± 0.003.26 ± 0.21
    6MVAi.m.1083.40 ± 0.003.41 ± 0.003.26 ± 0.21
    7MVAs.c.1083.10 ± 0.003.11 ± 0.003.56 ± 0.21
    8MVAi.d.1083.86 ± 0.212.95 ± 0.213.71 ± 0.00
    • ↵ a BALB/c mice were immunized with a single dose of PBS, Dryvax, or MVA at week 0 by the indicated routes of vaccination. Antisera were collected at week 6 and pooled, and the antibody levels against the indicated EV antigens were measured by ELISA. The results are the average of two independent immunization experiments in which each group contained three mice.

  • TABLE 2.

    Comparison of EV-specific antibody titers elicited by single immunizations and prime-boost immunizationsa

    GroupType of immunizationRouteDoseWk(s)Antibody titer (log10 ± SD) against EV antigen:
    A33RA56RB5R
    1PBSi.m.NA00.10 ± 0.000.10 ± 0.000.10 ± 0.00
    2Dryvaxi.d.10602.80 ± 0.002.80 ± 0.002.50 ± 0.00
    3Dryvaxi.d.10703.26 ± 0.213.11 ± 0.422.95 ± 0.64
    4MVAi.d.1080, 33.11 ± 0.423.56 ± 0.214.01 ± 0.00
    5MVAi.d.1080, 63.86 ± 0.213.86 ± 0.634.31 ± 0.42
    • ↵ a BALB/c mice were immunized with a single dose of PBS, Dryvax, or MVA at week 0 using indicated routes of vaccination. Mice in groups 4 and 5 received two doses of MVA given 3 weeks apart and 6 weeks apart, respectively. Mice in group 6 were immunized once with Dryvax by scarification at week 0. In groups 1 through 5, the results represent the average of two independent immunization experiments in which each group contained three mice.

PreviousNext
Back to top
Download PDF
Citation Tools
Characterization and Use of Mammalian-Expressed Vaccinia Virus Extracellular Membrane Proteins for Quantification of the Humoral Immune Response to Smallpox Vaccines
Alonzo D. García, Clement A. Meseda, Anne E. Mayer, Arunima Kumar, Michael Merchlinsky, Jerry P. Weir
Clinical and Vaccine Immunology Aug 2007, 14 (8) 1032-1044; DOI: 10.1128/CVI.00050-07

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Email

Thank you for sharing this Clinical and Vaccine Immunology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization and Use of Mammalian-Expressed Vaccinia Virus Extracellular Membrane Proteins for Quantification of the Humoral Immune Response to Smallpox Vaccines
(Your Name) has forwarded a page to you from Clinical and Vaccine Immunology
(Your Name) thought you would be interested in this article in Clinical and Vaccine Immunology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Characterization and Use of Mammalian-Expressed Vaccinia Virus Extracellular Membrane Proteins for Quantification of the Humoral Immune Response to Smallpox Vaccines
Alonzo D. García, Clement A. Meseda, Anne E. Mayer, Arunima Kumar, Michael Merchlinsky, Jerry P. Weir
Clinical and Vaccine Immunology Aug 2007, 14 (8) 1032-1044; DOI: 10.1128/CVI.00050-07
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Antibodies, Viral
Antigens, Viral
Membrane Proteins
Semliki forest virus
Smallpox Vaccine

Related Articles

Cited By...

About

  • About CVI
  • For Librarians
  • For Advertisers
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • Submit a Manuscript to mSphere

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 1556-6811; Online ISSN: 1556-679X